Page 1,982«..1020..1,9811,9821,9831,984..1,9902,000..»

BrainStorm gets FDA fast-track status for ALS stem cell therapy

Posted: October 7, 2014 at 8:41 pm

Published October 07, 2014

Major League Baseball Commissioner-elect Rob Manfred participates in the ALS Ice-Bucket Challenge outside the organization's headquarters in New York, Wednesday, Aug. 20, 2014. Manfred participated with more than 160 other MLB employees to raise more than $16,000 for the ALS Association. (AP Photo/Vanessa A. Alvarez)(AP2014)

Israel's BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a "fast-track" product for the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm's treatment, called NurOwn, is being studied in a mid-stage clinical trial in patients with ALS, also known as Lou Gehrig's Disease.

The FDA's fast track program is designed to speed up access to drugs intended to treat serious conditions and which have the potential to address unmet medical needs.

"The receipt of fast-track designation from the FDA is an acknowledgement of the unmet medical need in ALS," BrainStorm Chief Executive Tony Fiorino said on Tuesday.

"What is so valuable about fast track designation to a small company like BrainStorm is the opportunity to have increased meetings with and more frequent written communication from the FDA," he said, adding that only a small number of cellular therapies have received FDA approval.

BrainStorm said the last patient has completed the last visit in its phase 2a clinical trial in ALS at Hadassah Medical Center in Jerusalem. The company expects to release final results of the study in the fourth quarter of 2014.

NurOwn is also being studied in a phase 2 clinical trial at three sites in the United States.

According to the ALS Association, 5,600 people in the United States are diagnosed each year with the disease, which has severely disabled British physicist Stephen Hawking.

Originally posted here:
BrainStorm gets FDA fast-track status for ALS stem cell therapy

Posted in Stem Cell Therapy | Comments Off on BrainStorm gets FDA fast-track status for ALS stem cell therapy

Hylunia Educates Professional Customers on Anti-Aging Peptides and Stem Cells

Posted: October 7, 2014 at 7:46 pm

Henderson, NV (PRWEB) October 07, 2014

Stem cells from plants are becoming an increasingly popular way to turn the clock backward on skin aging. Hylunia's own light and silky Moisure Infusion contains plant stem cells and peptides that are thought to delay aging, making skin look softer smoother and younger.

Plant stem cells like the ones found in grapes are undifferentiated cells from the meristems of plants. Like human stem cells, they can replace damaged cells and renew themselves. Plant stem cells are cultured in labs, allowing scientists to have more control over the quality, quantity and purity of a plant's anti-aging substance.

Skin care stem cells are extracted from various plants, including tiny white Edelweiss flowers, a swamp plant called gotu kola, swiss apples, and raspberry cell cultures. Lilac and algae may also be used. Most of these products contain antioxidants and other chemicals that make skin look younger.

Hylunia's unique product features grape stem cells cultivated from the Gamay Teinturier Fraux grape from Burgundy, France. Their ingredient list explains that these grapes are "high in powerful antioxidants and [have] free radical scavenging capabilities."

The site adds that "The Grape Stem Cells contain special epigenetic factors and metabolites which are able to protect human stem cells against UV radiation and therefore delay aging." UV damage is responsible for up to 80% of skin aging.

Hylunia Moisture Infusion also contains peptides, which can boost collagen and block the neurotransmitters that contract the muscles that form wrinkles. They stimulate epidermal skin cells and increase skin healing and repair.

Hyluna's product contains Palmitoyl Trypeptide-5 (patented), which stimulates collagen synthesis to "strengthen skin and reduce the appearance of fine lines and wrinkles."

Hylunia is currently putting together a webinar about plant peptides for their professional customers like spa and salon owners. The webinar will be available soon.

Read the original here:
Hylunia Educates Professional Customers on Anti-Aging Peptides and Stem Cells

Posted in Stem Cells | Comments Off on Hylunia Educates Professional Customers on Anti-Aging Peptides and Stem Cells

Tracy Young-Pearse – Stem Cells and the Study of Neurodegeneration – Video

Posted: October 7, 2014 at 11:40 am


Tracy Young-Pearse - Stem Cells and the Study of Neurodegeneration
UCI MIND Presents: 25th Annual Southern California Alzheimer #39;s Disease Research Conference September 12, 2014 University of California, Irvine.

By: DUE Media Services at UC Irvine

Read more here:
Tracy Young-Pearse - Stem Cells and the Study of Neurodegeneration - Video

Posted in Stem Cell Videos | Comments Off on Tracy Young-Pearse – Stem Cells and the Study of Neurodegeneration – Video

Stem Cell Arthritis Treatment | limbus stem cells – Video

Posted: October 7, 2014 at 6:53 am


Stem Cell Arthritis Treatment | limbus stem cells
http://www.arthritistreatmentcenter.com Another major coup for stem cell research next Researchers regrow corneas using adult human stem cells Loren Grush re...

By: Nathan Wei

Read the original post:
Stem Cell Arthritis Treatment | limbus stem cells - Video

Posted in Stem Cells | Comments Off on Stem Cell Arthritis Treatment | limbus stem cells – Video

Curing cancer with stem cells | Sergey Zhidovinov | TEDxEkaterinburg – Video

Posted: October 7, 2014 at 6:53 am


Curing cancer with stem cells | Sergey Zhidovinov | TEDxEkaterinburg
This talk was given at a local TEDx event, produced independently of the TED Conferences. We all know how dangerous cancer is. Whole world is looking for the magic cure that will fight this...

By: TEDx Talks

See the article here:
Curing cancer with stem cells | Sergey Zhidovinov | TEDxEkaterinburg - Video

Posted in Stem Cells | Comments Off on Curing cancer with stem cells | Sergey Zhidovinov | TEDxEkaterinburg – Video

New technique allows scientists to find rare stem cells within bone marrow

Posted: October 7, 2014 at 6:53 am

PUBLIC RELEASE DATE:

6-Oct-2014

Contact: Sarah McDonnell s_mcd@mit.edu 617-253-8923 Massachusetts Institute of Technology @MITnews

CAMBRIDGE, MA -- Deep within the bone marrow resides a type of cells known as mesenchymal stem cells (MSCs). These immature cells can differentiate into cells that produce bone, cartilage, fat, or muscle a trait that scientists have tried to exploit for tissue repair.

In a new study that should make it easier to develop such stem-cell-based therapies, a team of researchers from MIT and the Singapore-MIT Alliance in Research and Technology (SMART) has identified three physical characteristics of MSCs that can distinguish them from other immature cells found in the bone marrow. Based on this information, they plan to create devices that could rapidly isolate MSCs, making it easier to generate enough stem cells to treat patients.

Until now, there has been no good way to separate MSCs from bone marrow cells that have already begun to differentiate into other cell types, but share the same molecules on the cell surface. This may be one reason why research results vary among labs, and why stem-cell treatments now in clinical trials are not as effective as they could be, says Krystyn Van Vliet, an MIT associate professor of materials science and engineering and biological engineering and a senior author of the paper, which appears in the Proceedings of the National Academy of Sciences this week.

"Some of the cells that you're putting in and calling stem cells are producing a beneficial therapeutic outcome, but many of the cells that you're putting in are not," Van Vliet says. "Our approach provides a way to purify or highly enrich for the stem cells in that population. You can now find the needles in the haystack and use them for human therapy."

Lead authors of the paper are W.C. Lee, a former graduate student at the National University of Singapore and SMART, and Hui Shi, a former SMART postdoc. Other authors are Jongyoon Han, an MIT professor of electrical engineering and biological engineering, SMART researchers Zhiyong Poon, L.M. Nyan, and Tanwi Kaushik, and National University of Singapore faculty members G.V. Shivashankar, J.K.Y. Chan, and C.T. Lim.

Physical markers

MSCs make up only a small percentage of cells in the bone marrow. Other immature cells found there include osteogenic cells, which have already begun the developmental path toward becoming cartilage- or bone-producing cells. Currently, researchers try to isolate MSCs based on protein markers found on the cell surfaces. However, these markers are not specific to MSCs and can also yield other types of immature cells that are more differentiated.

Continued here:
New technique allows scientists to find rare stem cells within bone marrow

Posted in Stem Cells | Comments Off on New technique allows scientists to find rare stem cells within bone marrow

Barcoding tool for stem cells developed

Posted: October 7, 2014 at 6:53 am

A 7-year-project to develop a barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: New data from Harvard Stem Cell Institute scientists at Boston Children's Hospital suggests, surprisingly, that the billions of blood cells that we produce each day are made not by blood stem cells, but rather their less pluripotent descendants, called progenitor cells. The researchers hypothesize that blood comes from stable populations of different long-lived progenitor cells that are responsible for giving rise to specific blood cell types, while blood stem cells likely act as essential reserves.

The work, supported by a National Institutes of Health Director's New Innovator Award and published in Nature, suggests that progenitor cells could potentially be just as valuable as blood stem cells for blood regeneration therapies.

This new research challenges what textbooks have long read: That blood stem cells maintain the day-to-day renewal of blood, a conclusion drawn from their importance in re-establishing blood cell populations after bone marrow transplants -- a fact that still remains true. But because of a lack of tools to study how blood forms in a normal context, nobody had been able to track the origin of blood cells without doing a transplant.

Boston Children's Hospital scientist Fernando Camargo, PhD, and his postdoctoral fellow Jianlong Sun, PhD, addressed this problem with a tool that generates a unique barcode in the DNA of all blood stem cells and their progenitor cells in a mouse. When a tagged cell divides, all of its descendant cells possess the same barcode. This biological inventory system makes it possible to determine the number of stem cells/progenitors being used to make blood and how long they live, as well as answer fundamental questions about where individual blood cells come from.

"There's never been such a robust experimental method that could allow people to look at lineage relationships between mature cell types in the body without doing transplantation," Sun said. "One of the major directions we can now go is to revisit the entire blood cell hierarchy and see how the current knowledge holds true when we use this internal labeling system."

"People have tried using viruses to tag blood cells in the past, but the cells needed to be taken out of the body, infected, and re-transplanted, which raised a number of issues," said Camargo, who is a member of Children's Stem Cell Program and an associate professor in Harvard University's Department of Stem Cell and Regenerative Biology. "I wanted to figure out a way to label blood cells inside of the body, and the best idea I had was to use mobile genetic elements called transposons."

A transposon is a piece of genetic code that can jump to a random point in DNA when exposed to an enzyme called transposase. Camargo's approach works using transgenic mice that possess a single fish-derived transposon in all of their blood cells. When one of these mice is exposed to transposase, each of its blood cells' transposons changes location. The location in the DNA where a transposon moves acts as an individual cell's barcode, so that if the mouse's blood is taken a few months later, any cells with the same transposon location can be linked back to its parent cell.

The transposon barcode system took Camargo and Sun seven years to develop, and was one of Camargo's first projects when he opened his own lab at the Whitehead Institute for Biomedical Research directly out of grad school. Sun joined the project after three years of setbacks, and accomplished an experimental tour de force to reach the conclusions in the Nature paper, which includes data on how many stem cells or progenitor cells contribute to the formation of immune cells in mouse blood.

With the original question of how blood arises in a non-transplant context answered, the researchers are now planning to explore many more applications for their barcode tool.

"We are also tremendously excited to use this tool to barcode and track descendants of different stem cells or progenitor cells for a range of conditions, from aging, to the normal immune response," Sun said. "We first used this technology for blood analysis, however, this system can also help address basic questions about cell populations in solid tissue. You can imagine being able to look at tumor progression or identify the precise origins of cancer cells that have broken off from a tumor and are now circulating in the blood."

Here is the original post:
Barcoding tool for stem cells developed

Posted in Stem Cells | Comments Off on Barcoding tool for stem cells developed

Barcoding tool for stem cells: New technology that tracks the origin of blood cells challenges scientific dogma

Posted: October 7, 2014 at 6:53 am

Oct 05, 2014 New genetic barcoding technology allows scientists to identify differences in origin between individual blood cells. Credit: Camargo Lab

A 7-year-project to develop a barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: New data from Harvard Stem Cell Institute scientists at Boston Children's Hospital suggests, surprisingly, that the billions of blood cells that we produce each day are made not by blood stem cells, but rather their less pluripotent descendants, called progenitor cells. The researchers hypothesize that blood comes from stable populations of different long-lived progenitor cells that are responsible for giving rise to specific blood cell types, while blood stem cells likely act as essential reserves.

The work, supported by a National Institutes of Health Director's New Innovator Award and published in Nature, suggests that progenitor cells could potentially be just as valuable as blood stem cells for blood regeneration therapies.

This new research challenges what textbooks have long read: That blood stem cells maintain the day-to-day renewal of blood, a conclusion drawn from their importance in re-establishing blood cell populations after bone marrow transplantsa fact that still remains true. But because of a lack of tools to study how blood forms in a normal context, nobody had been able to track the origin of blood cells without doing a transplant.

Boston Children's Hospital scientist Fernando Camargo, PhD, and his postdoctoral fellow Jianlong Sun, PhD, addressed this problem with a tool that generates a unique barcode in the DNA of all blood stem cells and their progenitor cells in a mouse. When a tagged cell divides, all of its descendant cells possess the same barcode. This biological inventory system makes it possible to determine the number of stem cells/progenitors being used to make blood and how long they live, as well as answer fundamental questions about where individual blood cells come from.

"There's never been such a robust experimental method that could allow people to look at lineage relationships between mature cell types in the body without doing transplantation," Sun said. "One of the major directions we can now go is to revisit the entire blood cell hierarchy and see how the current knowledge holds true when we use this internal labeling system."

"People have tried using viruses to tag blood cells in the past, but the cells needed to be taken out of the body, infected, and re-transplanted, which raised a number of issues," said Camargo, who is a member of Children's Stem Cell Program and an associate professor in Harvard University's Department of Stem Cell and Regenerative Biology. "I wanted to figure out a way to label blood cells inside of the body, and the best idea I had was to use mobile genetic elements called transposons."

A transposon is a piece of genetic code that can jump to a random point in DNA when exposed to an enzyme called transposase. Camargo's approach works using transgenic mice that possess a single fish-derived transposon in all of their blood cells. When one of these mice is exposed to transposase, each of its blood cells' transposons changes location. The location in the DNA where a transposon moves acts as an individual cell's barcode, so that if the mouse's blood is taken a few months later, any cells with the same transposon location can be linked back to its parent cell.

The transposon barcode system took Camargo and Sun seven years to develop, and was one of Camargo's first projects when he opened his own lab at the Whitehead Institute for Biomedical Research directly out of grad school. Sun joined the project after three years of setbacks, and accomplished an experimental tour de force to reach the conclusions in the Nature paper, which includes data on how many stem cells or progenitor cells contribute to the formation of immune cells in mouse blood.

With the original question of how blood arises in a non-transplant context answered, the researchers are now planning to explore many more applications for their barcode tool.

Continued here:
Barcoding tool for stem cells: New technology that tracks the origin of blood cells challenges scientific dogma

Posted in Stem Cells | Comments Off on Barcoding tool for stem cells: New technology that tracks the origin of blood cells challenges scientific dogma

Stem Cells, Malaria, and the Genetics of Drug Response Highlighted at Penn's 9th Annual Translational Medicine Symposium

Posted: October 7, 2014 at 6:53 am

Contact Information

Available for logged-in reporters only

Newswise PHILADELPHIA The University of Pennsylvanias Institute for Translational Medicine and Therapeutics 9th Annual International Symposium (ITMAT), Progress in Translational Science: Emerging Therapeutic Modalities, will be held on October 13-14. The symposium will feature outstanding speakers from the United States and abroad to address topics at the core of translational science. Speakers will include experts researching advances in stem cell biology, single cell metabolomics, and infectious diseases.

Date: Monday and Tuesday, October 13 - 14, 2013, starting at 8:30 am.

Location: Smilow Center for Translational Research, Rubenstein Auditorium and Lobby, 3400 Civic Center Blvd, Philadelphia, PA 19104

Additional details:

The symposium will feature presentations in six major areas:

Challenges and Opportunities in Translational Research Stem Cell Therapeutics Movement in Malaria Focus on the Single Cell Variability in Drug Response Translational Immunology

Garret A. FitzGerald, MD, Director of ITMAT, will host the event. Speakers and talks include:

Kenneth S. Zaret, PhD, Joseph Leidy Professor of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania Discovering networks and diagnostics for pancreatic cancer progression

Read more:
Stem Cells, Malaria, and the Genetics of Drug Response Highlighted at Penn's 9th Annual Translational Medicine Symposium

Posted in Stem Cells | Comments Off on Stem Cells, Malaria, and the Genetics of Drug Response Highlighted at Penn's 9th Annual Translational Medicine Symposium

Stem Cells, Malaria, and the Genetics of Drug Response at Translational Medicine Symposium

Posted: October 7, 2014 at 6:53 am

PUBLIC RELEASE DATE:

6-Oct-2014

Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine @PennMedNews

PHILADELPHIA The University of Pennsylvania's Institute for Translational Medicine and Therapeutics' 9th Annual International Symposium (ITMAT), Progress in Translational Science: Emerging Therapeutic Modalities, will be held on October 13-14. The symposium will feature outstanding speakers from the United States and abroad to address topics at the core of translational science. Speakers will include experts researching advances in stem cell biology, single cell metabolomics, and infectious diseases.

Date: Monday and Tuesday, October 13 - 14, 2013, starting at 8:30 am.

Location: Smilow Center for Translational Research, Rubenstein Auditorium and Lobby, 3400 Civic Center Blvd, Philadelphia, PA 19104

Additional Details

The symposium will feature presentations in six major areas:

Garret A. FitzGerald, MD, Director of ITMAT, will host the event. Speakers and talks include:

Carl H. June, MD, Richard W. Vague Professor in Immunotherapy, Program Director of Translational Research, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Driving CARs for cancer: are we there yet?

Read more:
Stem Cells, Malaria, and the Genetics of Drug Response at Translational Medicine Symposium

Posted in Stem Cells | Comments Off on Stem Cells, Malaria, and the Genetics of Drug Response at Translational Medicine Symposium

Page 1,982«..1020..1,9811,9821,9831,984..1,9902,000..»